CircRNA CDR1as/miR-641/HOXA9 pathway regulated stemness contributes to cisplatin resistance in non-small cell lung cancer (NSCLC)

Yongsheng Zhao,Renyan Zheng,Jian Chen,Dong Ning
DOI: https://doi.org/10.1186/s12935-020-01390-w
IF: 6.429
2020-07-06
Cancer Cell International
Abstract:Cisplatin (DDP) is the first-line chemotherapeutic drug for non-small cell lung cancer (NSCLC), and long-term DDP stimulation increased resistance of NSCLC cells to this drug by enriching cancer stem cells (CSCs), which contributed to recurrence and worse prognosis of NSCLC, but the molecular mechanisms are still not fully delineated.
oncology
What problem does this paper attempt to address?